A Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer

Inclusion Criteria: To be eligible to participate in this study, an individual must meet all of the following criteria: * Have a diagnosis of metastatic colorectal cancer previously treated with at least two lines of therapy for unresectable/metastatic disease * Have microsatellite stable disease * Adequate hematologic and end organ function Exclusion Criteria: An individual who meets any of the following criteria will be excluded from participation in this study: * Patients with known MSI-high status or known mismatch repair deficiency (dMMR) * Patients in whom both mismatch repair and microsatellite stability status are unknown * History of severe allergic, anaphylactic, or other hypersensitivity reactions to any of the study medications or their classes * Left-sided (at or distal to the splenic flexure) RAS/BRAF wild-type metastatic colorectal cancer who are EGFR inhibitor naïve. * Prior therapy with an anti-PD-1, anti-PD-L1, anti PD L2, anti-CD47, or anti-SIRPα agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX 40, CD137)